J&J oral psoriasis drug holds skin clearance through two years in phase 3 trial

Overview

Updated 1 hour ago

Johnson & Johnson unveiled two-year data from its phase 3 plaque psoriasis program on October 9. At week 112, at least 72% of patients on ICOTYDE (icotrokinra) had at least 90% skin clearance, and at least 70% reached clear or almost clear skin. Those rates held steady from week 64 through week 112.

ICOTYDE is the first oral peptide that precisely blocks the IL-23 receptor, a key driver of psoriatic inflammation. Patients take one pill daily on an empty stomach. Current high-efficacy psoriasis treatments are mostly injectable biologics, which many patients avoid or abandon. The new results suggest the pill's effectiveness now approaches that of injectables, with no new safety signals reported.

Why it matters

An oral pill now comes close to matching injectable-biologic efficacy in severe plaque psoriasis, giving patients who refuse injections a high-efficacy option for the first time.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

≥72%

PASI 90 response at week 112

Share of ICOTYDE-treated patients with at least 90% skin clearance at two years.

≥70%

Clear or almost clear skin

Patients achieving Investigator's Global Assessment score of 0 or 1 from week 64 through week 112.

≥44%

Complete skin clearance

Patients achieving a PASI 100 score, sustained from week 64 through week 112.

85%

Regained response after retreatment

PASI 90 responders withdrawn from the drug at week 24 who regained response within 24 weeks of restarting.

78%

Sustained itch improvement

Patients reporting clinically meaningful itch relief from week 64 to week 112.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Organizations Involved

Johnson & Johnson

Healthcare company

Developer and marketer of ICOTYDE (icotrokinra)

Johnson & Johnson is the pharmaceutical company that developed ICOTYDE, the first oral peptide targeting the IL-23 receptor for plaque psoriasis.

Timeline

2026 October 2026

3 events Latest: Today

October 2026
ICONIC-LEAD two-year results presented
Today Conference presentation

At Fall Clinical Dermatology, J&J showed at least 72% of patients hit PASI 90 and at least 70% reached clear or almost clear skin at week 112.
Today
ICONIC-TOTAL two-year data released
Data release

J&J reported durable clearance in scalp, genital, hand/foot and nail psoriasis through week 112, with no new safety signals.
7 days ago
2026
Randomized-withdrawal analysis published in JAAD
Publication

The Journal of the American Academy of Dermatology published findings that continued ICOTYDE maintained response better than withdrawal from weeks 24 to 52.
2026

Scenarios

ICOTYDE reaches blockbuster sales status

Possible Resolves by End of 2027

Discussed by: Pharmaceutical market analysts tracking J&J's Innovative Medicine portfolio

If the two-year durability data convert physicians who currently prescribe injectable biologics, ICOTYDE could become a major revenue driver. The oral dosing and strong efficacy create a plausible path to annual sales above $1 billion, the standard blockbuster threshold. J&J's quarterly earnings will be the scoreboard.

FDA approves ICOTYDE for psoriatic arthritis

Possible Resolves by End of 2028

Discussed by: Dermatology and rheumatology observers following the ICONIC program

Psoriasis and psoriatic arthritis often travel together, and a drug that blocks IL-23 in the skin is a natural candidate for the joint disease. If J&J files and wins an expanded indication, ICOTYDE would compete directly with injectable IL-23 biologics already approved for psoriatic arthritis.

Rival oral therapy posts head-to-head superiority

Uncertain Resolves by End of 2028

Discussed by: Competitors including Bristol Myers Squibb, whose oral TYK2 inhibitor Sotyktu already treats plaque psoriasis

ICOTYDE's oral advantage could narrow if a competitor's drug outperforms it in a head-to-head trial. Sotyktu (deucravacitinib) is the leading established oral rival, and other companies have oral programs targeting the same pathway. A decisive superiority result would reshape prescribing.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 2009

Stelara validates the IL-23 pathway (2009)

The FDA approved ustekinumab (Stelara), Johnson & Johnson's injectable antibody that blocks the shared IL-12/23 pathway, for moderate-to-severe plaque psoriasis. It was the first widely used drug targeting this inflammatory pathway.

Then

Stelara became a standard biologic for psoriasis and later for psoriatic arthritis and Crohn's disease.

Now

The IL-23 axis was confirmed as a central driver of psoriatic inflammation, setting up the next generation of more selective IL-23 inhibitors.

Why this matters now

ICOTYDE attacks the same pathway Stelara helped validate, but with an oral peptide instead of an injected antibody, a structural shift in how the pathway can be blocked.

March 2014

Otezla opens oral psoriasis treatment (2014)

The FDA approved apremilast (Otezla), an oral PDE4 inhibitor, first for psoriatic arthritis and then for plaque psoriasis, as the first oral non-biologic for the disease.

Then

Otezla gave patients an injection-free option but with modest efficacy, falling well short of biologic response rates.

Now

It proved oral drugs could win psoriasis prescriptions yet left the high-efficacy end of the market to injectables.

Why this matters now

ICOTYDE's data suggest the oral segment can now reach the efficacy that previously required injections, the gap Otezla never closed.

September 2022

Sotyktu brings the first oral targeted therapy (2022)

The FDA approved Bristol Myers Squibb's deucravacitinib (Sotyktu), an oral TYK2 inhibitor, for moderate-to-severe plaque psoriasis. It was the first oral therapy to selectively target the IL-23 pathway.

Then

Sotyktu became the leading oral alternative to injectable biologics, with response rates above placebo but below the top IL-17 and IL-23 antibodies.

Now

It established that oral targeted therapy could compete for first-line systemic use, creating the market ICOTYDE now enters.

Why this matters now

ICOTYDE is the direct challenger to Sotyktu in the oral targeted space, and its two-year durability data are the evidence J&J is using to claim superiority.